Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Dermal filler program with AbbVie in clinical phase - Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 - Ends 2023 with $26.7 million in cash and cash equivalents - Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT – REHOVOT, Israel, April 4, 2024 – CollPlant Biotechnologies (Nasdaq: CLG ...